Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study.
cannabis
childhood trauma
environment
functioning
psychosis
Journal
European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820
Informations de publication
Date de publication:
19 03 2021
19 03 2021
Historique:
pubmed:
20
3
2021
medline:
20
11
2021
entrez:
19
3
2021
Statut:
epublish
Résumé
A cumulative environmental exposure score for schizophrenia (exposome score for schizophrenia [ES-SCZ]) may provide potential utility for risk stratification and outcome prediction. Here, we investigated whether ES-SCZ was associated with functioning in patients with schizophrenia spectrum disorder, unaffected siblings, and healthy controls. This cross-sectional sample consisted of 1,261 patients, 1,282 unaffected siblings, and 1,525 healthy controls. The Global Assessment of Functioning (GAF) scale was used to assess functioning. ES-SCZ was calculated based on our previously validated method. The association between ES-SCZ and the GAF dimensions (symptom and disability) was analyzed by applying regression models in each group (patients, siblings, and controls). Additional models included polygenic risk score for schizophrenia (PRS-SCZ) as a covariate. ES-SCZ was associated with the GAF dimensions in patients (symptom: B = -1.53, p-value = 0.001; disability: B = -1.44, p-value = 0.001), siblings (symptom: B = -3.07, p-value < 0.001; disability: B = -2.52, p-value < 0.001), and healthy controls (symptom: B = -1.50, p-value < 0.001; disability: B = -1.31, p-value < 0.001). The results remained the same after adjusting for PRS-SCZ. The degree of associations of ES-SCZ with both symptom and disability dimensions were higher in unaffected siblings than in patients and controls. By analyzing an independent dataset (the Genetic Risk and Outcome of Psychosis study), we replicated the results observed in the patient group. Our findings suggest that ES-SCZ shows promise for enhancing risk prediction and stratification in research practice. From a clinical perspective, ES-SCZ may aid in efforts of clinical characterization, operationalizing transdiagnostic clinical staging models, and personalizing clinical management.
Sections du résumé
BACKGROUND
A cumulative environmental exposure score for schizophrenia (exposome score for schizophrenia [ES-SCZ]) may provide potential utility for risk stratification and outcome prediction. Here, we investigated whether ES-SCZ was associated with functioning in patients with schizophrenia spectrum disorder, unaffected siblings, and healthy controls.
METHODS
This cross-sectional sample consisted of 1,261 patients, 1,282 unaffected siblings, and 1,525 healthy controls. The Global Assessment of Functioning (GAF) scale was used to assess functioning. ES-SCZ was calculated based on our previously validated method. The association between ES-SCZ and the GAF dimensions (symptom and disability) was analyzed by applying regression models in each group (patients, siblings, and controls). Additional models included polygenic risk score for schizophrenia (PRS-SCZ) as a covariate.
RESULTS
ES-SCZ was associated with the GAF dimensions in patients (symptom: B = -1.53, p-value = 0.001; disability: B = -1.44, p-value = 0.001), siblings (symptom: B = -3.07, p-value < 0.001; disability: B = -2.52, p-value < 0.001), and healthy controls (symptom: B = -1.50, p-value < 0.001; disability: B = -1.31, p-value < 0.001). The results remained the same after adjusting for PRS-SCZ. The degree of associations of ES-SCZ with both symptom and disability dimensions were higher in unaffected siblings than in patients and controls. By analyzing an independent dataset (the Genetic Risk and Outcome of Psychosis study), we replicated the results observed in the patient group.
CONCLUSIONS
Our findings suggest that ES-SCZ shows promise for enhancing risk prediction and stratification in research practice. From a clinical perspective, ES-SCZ may aid in efforts of clinical characterization, operationalizing transdiagnostic clinical staging models, and personalizing clinical management.
Identifiants
pubmed: 33736735
doi: 10.1192/j.eurpsy.2021.19
pii: S0924933821000195
pmc: PMC8080213
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25Subventions
Organisme : Medical Research Council
ID : G08005009
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Références
Eur Psychiatry. 2012 Aug;27(6):463-9
pubmed: 21616646
Epidemiol Psychiatr Sci. 2020 Nov 17;29:e182
pubmed: 33200977
Psychol Med. 2018 Jan;48(2):229-244
pubmed: 28689498
World Psychiatry. 2020 Jun;19(2):199-205
pubmed: 32394548
Psychol Med. 2014 Feb;44(3):499-506
pubmed: 23701858
Curr Psychiatry Rep. 2019 Sep 14;21(10):100
pubmed: 31522306
Schizophr Bull. 2020 Dec 1;46(6):1353-1362
pubmed: 33259628
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
Arch Gen Psychiatry. 2011 Feb;68(2):148-57
pubmed: 21041608
JAMA Psychiatry. 2020 Dec 1;77(12):1296-1304
pubmed: 32805017
Biol Psychiatry. 2018 Nov 1;84(9):684-691
pubmed: 29807621
JAMA Psychiatry. 2019 Sep 1;76(9):966-975
pubmed: 31141099
Int J Methods Psychiatr Res. 2012 Sep;21(3):205-21
pubmed: 22419500
Mol Psychiatry. 2015 Feb;20(2):150-1
pubmed: 24888364
Schizophr Bull. 2018 Apr 6;44(3):584-592
pubmed: 28666366
Schizophr Bull. 2014 Jul;40(4):729-36
pubmed: 24860087
JAMA Psychiatry. 2018 Oct 1;75(10):985-986
pubmed: 29874362
JAMA Psychiatry. 2018 Jan 1;75(1):28-35
pubmed: 29167880
Span J Psychol. 2004 May;7(1):3-12
pubmed: 15139244
World Psychiatry. 2021 Feb;20(1):4-33
pubmed: 33432763
Arch Gen Psychiatry. 1992 Aug;49(8):615-23
pubmed: 1637251
Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
J Interpers Violence. 2013 May;28(7):1498-518
pubmed: 23266990
J Clin Psychiatry. 2012 May;73(5):632-8
pubmed: 22394457
Psychol Med. 2020 Aug;50(11):1884-1897
pubmed: 31414981
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
Psychol Med. 2019 Aug;49(11):1879-1889
pubmed: 30284529
World Psychiatry. 2019 Jun;18(2):173-182
pubmed: 31059627
Am J Psychiatry. 2004 Dec;161(12):2271-6
pubmed: 15569899
Transl Psychiatry. 2018 Aug 31;8(1):174
pubmed: 30171181
Psychol Med. 2019 Jan;49(2):325-334
pubmed: 29655375
Schizophr Res. 2016 Aug;175(1-3):161-167
pubmed: 27209524
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Trials. 2020 Feb 7;21(1):147
pubmed: 32033579
Psychopathology. 2006;39(4):175-8
pubmed: 16636640
Lancet Psychiatry. 2020 May;7(5):449-462
pubmed: 32004444
Child Abuse Negl. 2009 Aug;33(8):518-23
pubmed: 19758699
Schizophr Bull. 2003;29(3):587-93
pubmed: 14609251
Child Abuse Negl. 2003 Feb;27(2):169-90
pubmed: 12615092
Psychol Med. 2016 Nov;46(15):3127-3136
pubmed: 27534999
Am J Psychiatry. 2019 Jan 1;176(1):21-28
pubmed: 30392411
Arch Gen Psychiatry. 1976 Jun;33(6):766-71
pubmed: 938196
World Psychiatry. 2020 Jun;19(2):233-242
pubmed: 32394576
Psychol Med. 2018 Sep;48(12):1925-1936
pubmed: 29334044
Am J Hum Genet. 2008 Jul;83(1):132-5; author reply 135-9
pubmed: 18606306
Schizophr Bull. 2021 Mar 16;47(2):277-283
pubmed: 33215211
Arch Gen Psychiatry. 1988 Dec;45(12):1069-77
pubmed: 2848472
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Psychol Med. 2015 Oct;45(13):2727-36
pubmed: 26350397
Arch Gen Psychiatry. 1990 Jun;47(6):589-93
pubmed: 2190539
Acta Psychiatr Scand. 2019 Oct;140(4):295-312
pubmed: 31357235
Lancet Psychiatry. 2019 Oct;6(10):830-839
pubmed: 31519507
Schizophr Bull. 2018 Jun 6;44(4):710-719
pubmed: 29701807
Compr Psychiatry. 2007 Jan-Feb;48(1):88-94
pubmed: 17145287
Compr Psychiatry. 2012 Apr;53(3):292-8
pubmed: 21632038
Schizophr Bull. 2019 Sep 11;45(5):960-965
pubmed: 31508804
Schizophr Bull. 2018 Oct 17;44(6):1175-1179
pubmed: 30169883